Has reimbursement of bone mineral density testing and anti-osteoporotic treatments improved management of osteoporosis in France?

Bone

Volumn 47, Issue 4, 2010, Pages 790-794

  Canoui Poitrine, F ^a,b,f,g   Jaglal, S ^c   Chapurlat, R ^d   Tainturier, V ^e   Colin, C ^a,b   Schott, A M ^a,b,d  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITÉ DE LYON   (France)

^e Direction Régionale du Service Médical de l'Assurance Maladie   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g FACULTÉ DE MÉDECINE   (France)

Author keywords

Anti osteoporotic treatment; Bone mineral density testing; Osteoporosis; Repayment; Screening

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; PARATHYROID HORMONE[1-34]; RALOXIFENE; STRONTIUM RANELATE;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FRANCE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; POPULATION RESEARCH; PROSPECTIVE STUDY; REIMBURSEMENT; SCREENING TEST;

EID: 77956404864     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.06.026     Document Type: Article

References (19)

1. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 18(359(9319)):1761-1767.
2. Nevitt M.C., Cummings S.R. Non-skeletal determinants of fractures: the potential importance of the mechanics of falls. Study of Osteoporotic Fractures Research Group. Osteoporos Int 1994, 4(Suppl 1):67-70.
3. Nevitt M.C., Johnell O., Black D.M., Ensrud K., Genant H.K., Cummings S.R. Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group. Osteoporos Int 1994, 4(6):325-331.
4. Schott A.M., Cormier C., Hans D., Favier F., Hausherr E., Dargent-Molina P., et al. How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int 1998, 8(3):247-254.
5. Boonen S., Laan R.F., Barton I.P., Watts N.B. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005, 16(10):1291-1298.
6. Nguyen N.D., Eisman J.A., Nguyen T.V. Anti-hip fracture efficacy of bisphosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res 2006, 21(2):340-349.
7. Silverman S.L., Watts N.B., Delmas P.D., Lange J.L., Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007, 18(1):25-34.
8. Haute Autorité de Santé Prevention, diagnostic et traitement de l'ostéoporose. Haute Autorite de Santé 2006, http://www.has-sante.fr/.
9. Amamra N., Berr C., Clavel-Chapelon F., Delcourt C., Delmas P.D., Derriennic F., et al. Estimated number of women likely to benefit from bone mineral density measurement in France. Joint Bone Spine 2004, 71(5):409-418.
10. Roux C., Fardellone P., Lespessailles E., Cotte F.E., Mercier F., Gaudin A.F. Prevalence of risk factors for referring post-menopausal women for bone densitometry. The INSTANT study. Joint Bone Spine 2008, 75(6):702-707.
11. Lespessailles E., Cotte F.E., Roux C., Fardellone P., Mercier F., Gaudin A.F. Prevalence and features of osteoporosis in the French general population: the Instant study. Joint Bone Spine 2009, 76(4):394-400.
12. Martin-Latry K., Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can!. Pharmacoepidemiol Drug Saf 2010, 19(3):256-265.
13. Jaglal S.B., Weller I., Mamdani M., Hawker G., Kreder H., Jaakkimainen L., et al. Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong?. J Bone Miner Res 2005, 20(6):898-905.
14. Solomon D.H., Brookhart M.A., Gandhi T.K., Karson A., Gharib S., Orav E.J., et al. Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics. Am J Med 2004, 117(12):919-924.
15. Solomon D.H., Polinski J.M., Truppo C., Egan C., Jan S., Patel M., et al. Access to bone mineral density testing in patients at risk for osteoporosis. Osteoporos Int 2006, 17(12):1749-1754.
16. Cohen K., Maier D. Osteoporosis: evaluation of screening patterns in a primary-care group practice. J Clin Densitom 2008, 11(4):498-502.
17. Pressman A., Forsyth B., Ettinger B., Tosteson A.N. Initiation of osteoporosis treatment after bone mineral density testing. Osteoporos Int 2001, 12(5):337-342.
18. Cadarette S.M., Gignac M.A., Jaglal S.B., Beaton D.E., Hawker G.A. Access to osteoporosis treatment is critically linked to access to dual-energy x-ray absorptiometry testing. Med Care 2007, 45(9):896-901.
19. Lewiecki E.M., Baim S., Siri E.S. Osteoporosis care at risk in the United States. Osteoporos Int 2008, 19:1505-1509.